Boost Up Blog – Lifestyle
Author:
Scynexis
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 6, 2026
SCYNEXIS Announces $40.0 Million Private Placement
March 31, 2026
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
March 31, 2026
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
March 5, 2026